Login to Your Account

Listening to the MEDiator

miRagen's 'Good Problem': Heart Controls Metabolism via miR208a

By Anette Breindl
Science Editor

Tuesday, May 1, 2012
Last week was a busy one for Boulder, Colo.-based miRagen Therapeutics Inc. On Monday, the company announced it had completed a Series B round of $20 million. (See BioWorld Today, April 24, 2012.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription